echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Express treatment of non-small cell lung cancer, potential "first-in-class" therapy demonstrates anti-cancer activity

    Express treatment of non-small cell lung cancer, potential "first-in-class" therapy demonstrates anti-cancer activity

    • Last Update: 2022-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎WuXi AppTec content team editor

    Surface Oncology today announced its potential "first-in-class" antibody SRF388 as a monotherapy for patients
    with non-small cell lung cancer (NSCLC).
    Two patients with squamous NSCLC achieved a confirmed partial response, and one patient with NSCLC remained stable for more than a year
    .
    These patients have undergone upfront systemic treatment
    .
    Based on this positive result, Surface has begun a phase 2 clinical trial of SRF388 in combination with the anti-PD-1 antibody Keytruda (pembrolizumab), and expects to announce the results in the
    first half of next year.



    Lung cancer is one of the most common types of cancer and the leading cause of
    cancer death.
    In 2020 alone, more than 1.
    7 million people
    died of lung cancer worldwide.
    The pathological classification of lung cancer can be roughly divided into two categories: NSCLC and small cell lung cancer (SCLC), of which NSCLC is the highest lung cancer type, accounting for about 80%-85% of
    lung cancer cases.
    Most patients with non-small cell lung cancer are diagnosed at an advanced stage
    .


    SRF388 is a fully humanized antibody developed by Surface to inhibit the immunosuppressive cytokine IL-27
    .
    IL-27 has been found in certain tumor types to cause an inhibitory immune microenvironment, leading to tumor resistance to immune checkpoint inhibitors
    .
    For example, the researchers found that the IL-27 receptor signaling pathway contributes to the progression of hepatocellular carcinoma in mice, where IL-27 can act as an immune checkpoint to inhibit the activation of natural killer cells (NK) and innate immune cells
    .
    SRF388 can inhibit IL-27, thereby increasing the activation of natural killer cells and innate immune cells, and slowing down the progression of
    hepatocellular carcinoma.
    SRF388 has been granted orphan drug designation and fast-track designation by the US FDA for the treatment of liver cancer, and has the potential to become the first antibody
    targeting IL-27 for clinical use.


    IL-27's mechanism of action (Image source: Surface Oncology).


    According to the clinical data released this time, the objective response rate (ORR) of this trial examining SRF388 as a monotherapy for NSCLC was 22% (2/9)
    before the data deadline of August 24, 2022.
    It contains an ORR
    of 100% (2/2) in patients with squamous NSCLC.
    In addition, one of the adenocarcinoma patients showed long-lasting disease stability for more than 56 weeks
    .
    All three patients had previously received multiple lines of chemotherapy and anti-PD-(L)1 drugs and had relapsed
    .


    "We are excited to see SRF388 active as a monotherapy for recurrent NSCLC, a highly unmet medical need worldwide," said Dr.
    Rob Ross, CEO of Surface.
    To examine the possibility
    of SRF388 in combination with Keytruda as a 2- to 4-line therapy for patients with NSCLC.




    WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
    .
    If you have related business needs, please click the picture below to fill in the specific information
    .

    If you have any business needs, please long press to scan the QR code above, or
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.